Form 4: Trevi Therapeutics Director James V. Cassella Acquires 30,000 Stock Options

Director James V. Cassella acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Summary

• James V. Cassella, a director of Trevi Therapeutics, Inc., acquired 30,000 nonstatutory stock options on June 13, 2024.
• The exercise price of these options is $2.77.
• The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date, contingent upon continued service.
• The options expire on June 12, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports the acquisition of stock options by a director, which is a routine event.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date, contingent upon continued service.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, regarding the company's securities. This allows investors to monitor the actions of those with privileged information.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates